Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tofogliflozin - Chugai Pharmaceutical

Drug Profile

Tofogliflozin - Chugai Pharmaceutical

Alternative Names: Apleway; CSG452; Deberza; R 7201; RG 7201; RO4998452; Tofogliflozin hydrate

Latest Information Update: 10 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chugai Pharmaceutical
  • Developer Chugai Pharmaceutical; Kowa; Osaka University School of Medicine; Sanofi K.K.
  • Class Antihyperglycaemics; Benzhydryl compounds; Benzofurans; Cardiovascular therapies; Glucosides; Small molecules; Spiro compounds
  • Mechanism of Action Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Type 2 diabetes mellitus

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Phase II Atherosclerosis

Most Recent Events

  • 16 Sep 2019 Efficacy and adverse events data from the phase II STOP-OB trial in Type 2 diabetes presented at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD-2019)
  • 05 Jul 2019 Osaka University Graduate School of Medicine completes a phase II trial in Atherosclerosis in Japan (UMIN000017607)
  • 27 Feb 2019 Kowa completes a phase II STOP-OB trial in Type 2 diabetes (Adjunctive treatment, Treatment-experienced) in Japan (UMIN000026161)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top